Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 3;14(8):1621.
doi: 10.3390/pharmaceutics14081621.

Orally Dispersible Dosage Forms for Paediatric Use: Current Knowledge and Development of Nanostructure-Based Formulations

Andreea Cornilă  1 , Sonia Iurian  1 , Ioan Tomuță  1 , Alina Porfire  1
Affiliations
Review

Orally Dispersible Dosage Forms for Paediatric Use: Current Knowledge and Development of Nanostructure-Based Formulations

Andreea Cornilă et al. Pharmaceutics. .

Abstract

The paediatric population has always suffered from a lack of medicines tailored to their needs, especially in terms of accurate dosage, stability and acceptability. Orodispersible dosage forms have gone through a resurrection as an alternative to liquid formulations or fractioned solid formulations, although they are still subject to several inconveniences, among which the unpleasant taste and the low oral bioavailability of the API are the most significant hurdles in the way of achieving an optimal drug product. Nanostructures can address these inconveniences through their size and variety, owing to the plethora of materials that can be used in their manufacturing. Through the formation and functionalisation of nanostructures, followed by their inclusion in orodispersible dosage forms, safe, stable and acceptable medicines intended for paediatric use can be developed.

Keywords: nanostructure; oral bioavailability; orodispersible dosage forms; paediatric medicines; polymeric nanoparticles; taste-masking.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Advantages of ODx and unmet needs of these formulations. ODG—orodispersible granules; ODT—orodispersible tablet; OL—oral lyophilisate; ODF—orodispersible film.
Figure 2
Figure 2
Trends in ODx and nanostructure-based ODx research.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. European Commission Regulation (EC) No. 1901/2006 of the European Parliament and of the Council of 12 December 2006 on Medicinal Products for Paediatric Use and Amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No. 726/2004. [(accessed on 10 February 2022)]. Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32006R1901&q....
    1. van Riet-Nales D.A., Kozarewicz P., Aylward B., de Vries R., Egberts T.C.G., Rademaker C.M.A., Schobben A.F.A.M. Paediatric drug development and formulation design—A european perspective. AAPS PharmSciTech. 2017;18:241–249. doi: 10.1208/s12249-016-0558-3. - DOI - PubMed
    1. Preis M. Orally disintegrating films and mini-tablets—innovative dosage forms of choice for pediatric use. AAPS PharmSciTech. 2015;16:234–241. doi: 10.1208/s12249-015-0313-1. - DOI - PMC - PubMed
    1. van Riet-Nales D.A., Schobben A.F.A.M., Vromans H., Egberts T.C.G., Rademaker C.M.A. Safe and effective pharmacotherapy in infants and preschool children: Importance of formulation aspects. Arch. Dis. Child. 2016;101:662–669. doi: 10.1136/archdischild-2015-308227. - DOI - PMC - PubMed
    1. Slavkova M., Breitkreutz J. Orodispersible drug formulations for children and elderly. Eur. J. Pharm. Sci. 2015;75:2–9. doi: 10.1016/j.ejps.2015.02.015. - DOI - PubMed

LinkOut - more resources